David E. Lazar's Investment in NovaBay Pharmaceuticals

David E. Lazar has filed a Schedule 13D with the SEC regarding his investment in NovaBay Pharmaceuticals, Inc. Lazar has acquired 179,748 shares of common stock and has the right to acquire additional shares through the conversion of Series D and Series E Preferred Stock. The total investment amounts to $3.85 million for Series D Preferred Stock and an additional $2.15 million for Series E Preferred Stock. Lazar has been appointed as the Chief Executive Officer and a member of the Board of Directors of NovaBay. The filing also details a Voting Agreement with Poplar Point Capital entities, which grants Lazar shared voting power over 1,020,300 shares. The investment is based on Lazar's belief that the shares were undervalued and represent an attractive investment opportunity. The filing indicates that Lazar may seek to increase or decrease his position in the company depending on market conditions and other factors.